In Brief: Microbiology Devices Panel
This article was originally published in The Gray Sheet
Executive Summary
Microbiology Devices Panel: FDA advisory panel unanimously votes (5-0) in favor of downclassification of automated short-term incubation cycle antimicrobial susceptibility devices from Class III to Class II at a Feb. 13 meeting in Rockville, Maryland. BioMerieux Vitek requested the downclassification in a petition submitted to the agency on July 24, 1997 ("The Gray Sheet" Aug. 18, I&W-6). Special controls recommended by the panel include an updated version of FDA's "Review Criteria for the Assessment of Antimicrobial Susceptibility Devices"...
You may also be interested in...
EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: